Premium
Treatment of Supraventricular Tachyarrhythmias with Intravenous Calcium Channel Blockers: Are Subtle Differences Worth the Cost?
Author(s) -
Cheiman Dina M.,
Shea Brian F.,
Kelly Ralph A.
Publication year - 1996
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/j.1875-9114.1996.tb03002.x
Subject(s) - medicine , diltiazem , verapamil , supraventricular arrhythmia , atrial fibrillation , atrial flutter , cardiology , clinical trial , drug , anesthesia , fibrillation , calcium , pharmacology
Verapamil and diltiazem are effective in terminating paroxysmal supraventricular tachycardias and slowing ventricular response during atrial fibrillation or flutter. Results from clinical trials for each individual drug demonstrate comparative efficacy rates, and both drugs share the same contraindications and relative precautions. Well‐designed comparative clinical trials are needed to establish if either drug has any clinical advantages in a particular patient population.